ArticleJournal of ultrasound2026
Before treatment alters the picture: ultrasound and metabolic biomarkers in treatment-naïve MASLD-the modifying role of BMI.
Article in Journal of ultrasound, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveB-mode ultrasonography is widely used to assess hepatic steatosis in MASLD. The associations between ultrasound-assessed steatosis, liver size, and metabolic abnormalities have previously been studied without considering whether the patients had received treatment. Medications may modify liver enzymes, glycemic indices, lipid profiles, and body weight and may strongly affect these relationships. Therefore, we aimed to evaluate hepatic echogenicity grade and liver size in relation to body mass index (BMI) and metabolic markers in newly diagnosed, treatment-naïve MASLD patients. MATERIALS AND
methodsIn this cross-sectional study, 122 adults with MASLD, as confirmed by a gastroenterologist, were enrolled. Hepatic echogenicity and cranio-caudal liver length were assessed using B-mode ultrasonography. Metabolic parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides (TG), total bilirubin, and glycated hemoglobin (HbA1c), were analyzed. Kruskal-Wallis and Mann-Whitney U tests were used for group comparisons, while Spearman's correlation and regression models were used to assess associations, including the modifying effect of BMI.
resultsIn unadjusted group comparisons, ALT, AST, and HbA1c differed across steatosis grades after Benjamini-Hochberg correction, whereas total cholesterol and triglycerides showed no consistent pattern. Hepatomegaly was associated with higher BMI, ALT, AST, and HbA1c. In adjusted models, grade×BMI interactions were negative for ALT and AST (both P < 0.001), whereas the adjusted grade association between steatosis grade and HbA1c was not significant (P = 0.324). After adjustment for BMI, steatosis grade, age, and sex, liver length remained associated with ALT (β = 0.073, 95% CI 0.046 to 0.100) and AST (β = 0.062, 95% CI 0.033 to 0.092).
conclusionIn treatment-naïve adults with MASLD, ultrasound-assessed steatosis grade and liver size were associated with selected metabolic and biochemical measures. Negative grade×BMI interactions were observed for ALT and AST, while the adjusted association between steatosis grade and HbA1c was not significant. These findings should be interpreted cautiously in the context of the study's design.
Indexed as
Identifiers
42905394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.